2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13A.04 A Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC

EP.13A.04 A Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC

Back to course

Pdf Summary

This study explores the combination of surufatinib and low-dose topotecan for the second or third-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) with multiple distant organ metastases. Surufatinib targets multiple receptors, demonstrating potential when existing therapies fail, while topotecan is already approved for second-line SCLC treatment. This research investigated the efficacy and safety of these drugs combined.<br /><br />The study involved 25 participants over 18 years old, all of whom had undergone prior treatment with at least one platinum-based regimen and showed disease progression. Surufatinib was administered daily, with topotecan given over a 5-day cycle every 3 weeks, until disease progression, unacceptable toxicity, or death occurred. Primary endpoint was progression-free survival (PFS), with secondary measures including objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<br /><br />The median follow-up lasted 10.6 months, with the median PFS at 4.2 months and median OS at 7.43 months. The ORR was 12.0%, while the DCR reached 80.0%. No complete responses were observed, but three patients had a partial response, and 17 maintained stable disease. Key side effects included neutropenia, leukopenia, thrombocytopenia, and hypertension, with higher-grade adverse events predominantly being hematologic. Overall, the safety profile was considered manageable with no new unexpected reactions.<br /><br />The surufatinib and low-dose topotecan combination showed promising efficacy and a tolerable safety profile, providing a potential viable option for second or third-line treatment in patients with ES-SCLC and multiple organ metastases, addressing a significant therapeutic gap in advanced-stage cancer care.

Asset Subtitle

Yingying Du

Meta Tag

Speaker Yingying Du

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

surufatinib

topotecan

ES-SCLC

small-cell lung cancer

second-line treatment

progression-free survival

objective response rate

disease control rate

adverse events

metastases